ATG9B

Summary

ATG9B (autophagy related 9B, HGNC:21899) is a protein-coding gene on chromosome 7q36.1, encoding Autophagy-related protein 9B (Q674R7). Phospholipid scramblase involved in autophagy by mediating autophagosomal membrane expansion.

This gene functions in the regulation of autophagy, a lysosomal degradation pathway. This gene also functions as an antisense transcript in the posttranscriptional regulation of the endothelial nitric oxide synthase 3 gene, which has 3’ overlap with this gene on the opposite strand. Mutations in this gene and disruption of the autophagy process have been associated with multiple cancers. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 285973 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 219 total — 1 likely-pathogenic
• MANE Select transcript: NM_001317056

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21899
Approved symbol	ATG9B
Name	autophagy related 9B
Location	7q36.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14885, APG9L2, SONE
Ensembl gene	ENSG00000181652
Ensembl biotype	protein_coding
OMIM	612205
Entrez	285973

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 5 protein_coding_CDS_not_defined, 3 retained_intron, 2 protein_coding, 1 nonsense_mediated_decay

ENST00000404733, ENST00000466157, ENST00000469530, ENST00000471797, ENST00000473134, ENST00000473409, ENST00000476282, ENST00000498521, ENST00000605952, ENST00000617967, ENST00000639579

RefSeq mRNA: 1 — MANE Select: NM_001317056 NM_001317056

CCDS: CCDS83242

Canonical transcript exons

ENST00000639579 — 14 exons

Exon	Start	End
ENSE00003497448	151023687	151023730
ENSE00003530541	151021188	151021329
ENSE00003593290	151023045	151023206
ENSE00003611101	151016109	151016235
ENSE00003623396	151023445	151023509
ENSE00003713884	151016431	151016527
ENSE00003720660	151018620	151019374
ENSE00003723700	151017871	151018050
ENSE00003732631	151018294	151018447
ENSE00003734644	151015882	151016023
ENSE00003750613	151016688	151016821
ENSE00003752626	151015151	151015713
ENSE00003754302	151017036	151017272
ENSE00003928425	151023874	151024494

Expression profiles

Bgee: expression breadth ubiquitous, 179 present calls, max score 99.04.

FANTOM5 (CAGE): breadth broad, TPM avg 1.9862 / max 289.7789, expressed in 408 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
86849	1.1719	171
86845	0.3414	132
86847	0.2060	71
86850	0.1345	47
86848	0.1182	55
86846	0.0144	3

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	99.04	gold quality
skin of leg	UBERON:0001511	92.98	gold quality
skin of abdomen	UBERON:0001416	90.74	gold quality
esophagus mucosa	UBERON:0002469	90.26	gold quality
right testis	UBERON:0004534	89.13	gold quality
upper arm skin	UBERON:0004263	88.67	gold quality
left testis	UBERON:0004533	88.57	gold quality
right uterine tube	UBERON:0001302	87.95	gold quality
zone of skin	UBERON:0000014	87.79	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.98	gold quality
adenohypophysis	UBERON:0002196	85.73	gold quality
pituitary gland	UBERON:0000007	84.82	gold quality
testis	UBERON:0000473	84.44	gold quality
buccal mucosa cell	CL:0002336	83.48	gold quality
esophagus squamous epithelium	UBERON:0006920	83.46	gold quality
amniotic fluid	UBERON:0000173	81.50	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	80.31	gold quality
bronchial epithelial cell	CL:0002328	80.26	gold quality
sperm	CL:0000019	79.84	gold quality
cortical plate	UBERON:0005343	79.19	gold quality
vagina	UBERON:0000996	78.94	gold quality
decidua	UBERON:0002450	78.89	gold quality
placenta	UBERON:0001987	78.86	gold quality
bronchus	UBERON:0002185	78.67	gold quality
spleen	UBERON:0002106	77.89	gold quality
esophagus	UBERON:0001043	77.47	gold quality
nucleus accumbens	UBERON:0001882	77.39	gold quality
hypothalamus	UBERON:0001898	76.93	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	75.64	gold quality
ectocervix	UBERON:0012249	73.71	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-9543	yes	9.37
E-ANND-3	yes	9.29
E-MTAB-10018	no	296.89

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 7)

• APG9L2 is highly expressed in placenta (trophoblast cells) and pituitary gland of adult tissues. (PMID:15755735)
• The role of Atg9 trafficking in yeast and mammalian autophagy, is summarised. (PMID:20083107)
• This study highlights the transcriptional inactivation mechanisms of ATG2B, ATG4D, ATG9A and ATG9B promoter methylation status and the possible origin of autophagy signal pathway repression in invasive ductal carcinomas. (PMID:27265029)
• Aging is associated with a decline in Atg9b-mediated autophagosome formation and appearance of enlarged mitochondria in the heart. (PMID:32627317)
• Contribution of NOS3AS Variants to Susceptibility to Essential Hypertension: A Study in Kermanshah Province, Western Iran. (PMID:36966459)
• ATG9B is a tissue-specific homotrimeric lipid scramblase that can compensate for ATG9A. (PMID:37938170)
• Depletion of CPNE7 sensitizes colorectal cancer to 5-fluorouracil by downregulating ATG9B expression. (PMID:38526029)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	atg9b	ENSDARG00000055292
mus_musculus	Atg9b	ENSMUSG00000038295
rattus_norvegicus	Atg9b	ENSRNOG00000023449
drosophila_melanogaster	Atg9	FBGN0034110
caenorhabditis_elegans		WBGENE00020706

Paralogs (1): ATG9A (ENSG00000198925)

Protein

Protein identifiers

Autophagy-related protein 9B — Q674R7 (reviewed: Q674R7)

Alternative names: APG9-like 2, Nitric oxide synthase 3-overlapping antisense gene protein

All UniProt accessions (1): Q674R7

UniProt curated annotations — full annotation on UniProt →

Function. Phospholipid scramblase involved in autophagy by mediating autophagosomal membrane expansion. Cycles between the preautophagosomal structure/phagophore assembly site (PAS) and the cytoplasmic vesicle pool and supplies membrane for the growing autophagosome. Lipid scramblase activity plays a key role in preautophagosomal structure/phagophore assembly by distributing the phospholipids that arrive through ATG2 (ATG2A or ATG2B) from the cytoplasmic to the luminal leaflet of the bilayer, thereby driving autophagosomal membrane expansion. In addition to autophagy, also plays a role in necrotic cell death.

Subunit / interactions. Homotrimer; forms a homotrimer with a central pore that forms a path between the two membrane leaflets.

Subcellular location. Preautophagosomal structure membrane.

Tissue specificity. Highly expressed in placenta (trophoblast cells) and pituitary gland. Not expressed in vascular endothelial.

Domain organisation. Forms a homotrimer with a solvated central pore, which is connected laterally to the cytosol through the cavity within each protomer. Acts as a lipid scramblase that uses its central pore to function: the central pore opens laterally to accommodate lipid headgroups, thereby enabling lipid flipping and redistribution of lipids added to the outer leaflet of ATG9B-containing vesicles, thereby enabling growth into autophagosomes. The tyrosine-based sorting signal motif, also named YXX-psi motif, promotes interaction with the AP-4 complex.

Induction. By hypoxia, leading to inhibit NOS3 expression.

Miscellaneous. ATG9B gene is located on the opposite DNA strand of the NOS3 gene at chromosome 7q36. The genes are oriented in a tail-to-tail configuration and the mRNAs encoding ATG9B and NOS3 are complementary for 662 nucleotides. ATG9B transcription may a role in NOS3 transcription regulation.

Similarity. Belongs to the ATG9 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q674R7-1	1	yes
Q674R7-2	2
Q674R7-3	3

RefSeq proteins (1): NP_001303985* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007241	Autophagy-rel_prot_9	Family

Pfam: PF04109

Catalyzed reactions (Rhea), 3 shown:

• a 1,2-diacyl-sn-glycero-3-phosphocholine(in) = a 1,2-diacyl-sn-glycero-3-phosphocholine(out) (RHEA:38571)
• a 1,2-diacyl-sn-glycero-3-phospho-L-serine(in) = a 1,2-diacyl-sn-glycero-3-phospho-L-serine(out) (RHEA:38663)
• a 1,2-diacyl-sn-glycero-3-phosphoethanolamine(in) = a 1,2-diacyl-sn-glycero-3-phosphoethanolamine(out) (RHEA:38895)

UniProt features (32 total): topological domain 7, compositionally biased region 6, transmembrane region 4, splice variant 4, sequence conflict 4, intramembrane region 2, region of interest 2, chain 1, short sequence motif 1, sequence variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8POE	ELECTRON MICROSCOPY	4.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q674R7-F1	69.20	0.37

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-1632852	Macroautophagy
R-HSA-9612973	Autophagy

MSigDB gene sets: 110 (showing top): GOBP_VACUOLE_ORGANIZATION, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_PLASMA_MEMBRANE_ORGANIZATION, GOBP_REGULATION_OF_MEMBRANE_LIPID_DISTRIBUTION, GOBP_MACROAUTOPHAGY, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_UP, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_BONE_DEVELOPMENT, GOCC_TRANS_GOLGI_NETWORK, GOBP_ORGANELLE_ASSEMBLY, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION, GOBP_PHOSPHOLIPID_TRANSPORT, GOBP_MEMBRANE_ORGANIZATION

GO Biological Process (10): autophagosome assembly (GO:0000045), mitophagy (GO:0000423), protein localization to phagophore assembly site (GO:0034497), piecemeal microautophagy of the nucleus (GO:0034727), bone morphogenesis (GO:0060349), reticulophagy (GO:0061709), programmed necrotic cell death (GO:0097300), lipid transport (GO:0006869), autophagy (GO:0006914), plasma membrane phospholipid scrambling (GO:0017121)

GO Molecular Function (1): phospholipid scramblase activity (GO:0017128)

GO Cellular Component (9): Golgi membrane (GO:0000139), phagophore assembly site (GO:0000407), autophagosome (GO:0005776), endoplasmic reticulum membrane (GO:0005789), trans-Golgi network (GO:0005802), phagophore assembly site membrane (GO:0034045), recycling endosome membrane (GO:0055038), cytoplasm (GO:0005737), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Autophagy	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
macroautophagy	2
Atg12 activating enzyme activity	1
protein-phosphatidylethanolamide deconjugating activity	1
Atg12 conjugating enzyme activity	1
Atg12 ligase activity	1
organelle assembly	1
Atg1/ULK1 kinase complex assembly	1
autophagosome organization	1
autophagy of mitochondrion	1
autophagosome assembly	1
intracellular protein localization	1
microautophagy	1
nucleophagy	1
nucleus disassembly	1
animal organ morphogenesis	1
skeletal system morphogenesis	1
bone development	1
programmed cell death	1
transport	1
lipid localization	1
catabolic process	1
transmembrane transport	1
process utilizing autophagic mechanism	1
plasma membrane organization	1
phospholipid translocation	1
plasma membrane phospholipid scrambling	1
intramembrane lipid carrier activity	1
Golgi apparatus	1
bounding membrane of organelle	1
cytoplasm	1
vacuole	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
Golgi apparatus subcompartment	1
phagophore assembly site	1
membrane	1
endosome membrane	1
recycling endosome	1

Protein interactions and networks

STRING

1002 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ATG9B	WIPI1	Q5MNZ9	803
ATG9B	ATG2B	Q96BY7	772
ATG9B	MAP1LC3A	Q9H492	769
ATG9B	ATG16L2	Q8NAA4	715
ATG9B	ATG12	O94817	711
ATG9B	ATG5	Q9H1Y0	709
ATG9B	UVRAG	Q9P2Y5	703
ATG9B	ATG4C	Q96DT6	686
ATG9B	BECN1	Q14457	678
ATG9B	ATG2A	Q2TAZ0	675
ATG9B	ATG10	Q9H0Y0	665
ATG9B	ATG3	Q9NT62	665
ATG9B	ATG7	O95352	664
ATG9B	ATG4A	Q8WYN0	657
ATG9B	ATG4D	Q86TL0	655

IntAct

13 interactions, top by confidence:

A	B	Type	Score
KIF3A	KIF3C	psi-mi:“MI:0914”(association)	0.730
CAPZA2	CNOT1	psi-mi:“MI:0914”(association)	0.640
LACC1	DUSP14	psi-mi:“MI:0914”(association)	0.530
FBXL4	DUSP14	psi-mi:“MI:0914”(association)	0.530
ATG9B	GTF2IRD1	psi-mi:“MI:0915”(physical association)	0.400
KIF3A	MAP1LC3B2	psi-mi:“MI:0914”(association)	0.350
PTDSS1	IGLL5	psi-mi:“MI:0914”(association)	0.350
ATG9B	PHKG2	psi-mi:“MI:0914”(association)	0.350
PEMT	FABP7	psi-mi:“MI:0914”(association)	0.350
PLD5	MACROH2A1	psi-mi:“MI:0914”(association)	0.350

BioGRID (32): ATG9B (Affinity Capture-MS), ATG9B (Affinity Capture-MS), ATG9B (Affinity Capture-MS), ATG9B (Affinity Capture-MS), ATG9B (Two-hybrid), ATG9B (Two-hybrid), ATG9B (Affinity Capture-MS), FBXO3 (Affinity Capture-MS), PHKG2 (Affinity Capture-MS), ATG9B (Affinity Capture-MS), ATG9B (Affinity Capture-MS), ATG9B (Affinity Capture-MS), GTF2IRD1 (Affinity Capture-MS), ATG9B (Affinity Capture-MS), ATG9B (Affinity Capture-MS)

ESM2 similar proteins: A3KN95, A4IFG4, A7E2I7, E2RDP2, J3QMI4, O94810, O95382, P0C5W1, P23677, P82350, Q15628, Q16586, Q1RMX3, Q24JP5, Q28686, Q29RH2, Q3T904, Q3U0S6, Q45T69, Q49LS1, Q5FWU3, Q5RCS0, Q5U651, Q64255, Q674R7, Q684M2, Q68FE2, Q68FE7, Q6EBV9, Q6GQT5, Q6NY19, Q6P9Q4, Q6PEY1, Q7Z3C6, Q80WF4, Q80XF7, Q86TL0, Q86XJ0, Q8C052, Q8C152

Diamond homologs: A1DNW0, A7KAM0, Q1E6Q3, Q2UUT6, Q3T904, Q4WLT9, Q54NA3, Q5FWU3, Q5RCS0, Q674R7, Q68FE2, Q6CT08, Q6EBV9, Q75A48, Q7Z3C6, Q876N4, A2QLJ9, Q51WZ9

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
TFE3	“up-regulates quantity by expression”	ATG9B	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

219 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	163
Likely benign	15
Benign	9

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
929759	NM_001317056.2(ATG9B):c.1480G>T (p.Glu494Ter)	Likely pathogenic

SpliceAI

3155 predictions. Top by Δscore:

Variant	Effect	Δscore
7:151013723:GACC:G	acceptor_gain	1.0000
7:151013886:G:GT	donor_gain	1.0000
7:151013915:GCGG:G	donor_gain	1.0000
7:151013918:GGTG:G	donor_loss	1.0000
7:151013919:G:C	donor_loss	1.0000
7:151013919:G:GG	donor_gain	1.0000
7:151013920:T:A	donor_loss	1.0000
7:151014002:C:CA	acceptor_gain	1.0000
7:151014003:GACA:G	acceptor_loss	1.0000
7:151014004:ACAG:A	acceptor_loss	1.0000
7:151014005:CA:C	acceptor_loss	1.0000
7:151014006:A:AG	acceptor_gain	1.0000
7:151014006:AG:A	acceptor_gain	1.0000
7:151014007:G:A	acceptor_loss	1.0000
7:151014007:G:GG	acceptor_gain	1.0000
7:151014007:GG:G	acceptor_gain	1.0000
7:151016231:TGAAG:T	acceptor_gain	1.0000
7:151016232:GAAG:G	acceptor_gain	1.0000
7:151016233:AAG:A	acceptor_gain	1.0000
7:151016234:AG:A	acceptor_gain	1.0000
7:151016236:C:CC	acceptor_gain	1.0000
7:151016240:A:C	acceptor_gain	1.0000
7:151016426:CTCA:C	donor_loss	1.0000
7:151016429:A:AC	donor_gain	1.0000
7:151016429:AC:A	donor_gain	1.0000
7:151016430:C:CT	donor_gain	1.0000
7:151016430:CC:C	donor_gain	1.0000
7:151016430:CCT:C	donor_gain	1.0000
7:151016430:CCTG:C	donor_gain	1.0000
7:151016523:CAGAG:C	acceptor_gain	1.0000

AlphaMissense

5875 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:151017192:G:C	F711L	0.995
7:151017192:G:T	F711L	0.995
7:151017194:A:G	F711L	0.995
7:151017958:A:C	F655L	0.994
7:151017958:A:T	F655L	0.994
7:151017960:A:G	F655L	0.994
7:151017946:G:C	F659L	0.993
7:151017946:G:T	F659L	0.993
7:151017948:A:G	F659L	0.993
7:151017193:A:G	F711S	0.992
7:151017913:A:C	C670W	0.991
7:151019259:C:G	R360P	0.991
7:151019251:G:T	R363S	0.990
7:151019260:G:T	R360S	0.990
7:151018859:G:C	N493K	0.989
7:151018859:G:T	N493K	0.989
7:151021215:A:C	F312L	0.989
7:151021215:A:T	F312L	0.989
7:151021217:A:G	F312L	0.989
7:151023703:T:A	D193V	0.989
7:151019240:G:C	N366K	0.988
7:151019240:G:T	N366K	0.988
7:151021216:A:G	F312S	0.988
7:151017914:C:T	C670Y	0.987
7:151017923:C:A	G667V	0.987
7:151017923:C:T	G667E	0.987
7:151017944:G:A	T660I	0.987
7:151019351:C:A	W329C	0.987
7:151019351:C:G	W329C	0.987
7:151019239:A:C	Y367D	0.986

dbSNP variants (sampled 300 via entrez): RS1000204701 (7:151018256 CA>C), RS1000281042 (7:151016961 T>C,G), RS1000362669 (7:151013486 G>A,C,T), RS1000880377 (7:151012987 G>A,T), RS1000885845 (7:151021498 A>G), RS1001099345 (7:151011955 G>A,C), RS1001235123 (7:151015637 A>T), RS1001840124 (7:151014450 T>C), RS1002320767 (7:151015782 AC>A,ACC), RS1002657834 (7:151014603 T>G), RS1002834049 (7:151013545 C>G,T), RS1002897799 (7:151018329 A>T), RS1003340191 (7:151018310 A>C,T), RS1003416013 (7:151019653 T>G), RS1003533294 (7:151024359 G>A,C,T)

Disease associations

OMIM: gene MIM:612205 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003476_9	Eyebrow thickness	7.000000e-06
GCST012490_554	Femur bone mineral density x serum urate levels interaction	4.000000e-12

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004531	urate measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	increases abundance, increases expression	2
Cadmium Chloride	increases expression	2
Particulate Matter	increases expression, decreases expression, decreases reaction, increases abundance	2
sotorasib	affects cotreatment, decreases expression	1
bisphenol A	affects cotreatment, decreases methylation	1
stearic acid	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
di-n-butylphosphoric acid	affects expression	1
trovafloxacin	increases expression, increases reaction	1
abrine	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases expression, decreases reaction	1
licochalcone B	increases expression	1
bisphenol S	decreases expression	1
trametinib	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Fulvestrant	affects cotreatment, decreases methylation	1
Arsenic	affects methylation	1
Vehicle Emissions	decreases reaction, decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Folic Acid	decreases expression	1
Lipopolysaccharides	decreases expression, affects response to substance, increases expression	1
Nickel	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Smoke	increases abundance, increases expression	1
Sodium Dodecyl Sulfate	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists